Jaguar Health Showcases Novel Plant-Based Gastrointestinal Medicines in Latest Corporate Presentation

Reuters12-11

Jaguar Health Showcases Novel Plant-Based Gastrointestinal Medicines in Latest Corporate Presentation

Jaguar Health Inc. $(JAGX)$ has provided updates on its ongoing efforts to develop plant-based medicines targeting gastrointestinal disorders. The company highlighted progress with its FDA-approved product Mytesi (crofelemer 125mg delayed-release tablets), used for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar also noted the conditional FDA approval renewal of Canalevia-CA1 for the treatment of chemotherapy-induced diarrhea in dogs, with a confirmatory effectiveness trial expected to conclude in February 2026. Additionally, the presentation discussed the OnTarget study, emphasizing its significance as a first-of-its-kind trial and outlining next steps, including filing a final study report and completing a patient survey regarding diarrhea reduction. The company is also preparing for future studies in metastatic breast cancer patients and exploring expanded access for those not qualifying for enrollment. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief on December 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590317537?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-11 03:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590317537","market":"us","top_or_hot":-1,"title":"Jaguar Health Showcases Novel Plant-Based Gastrointestinal Medicines in Latest Corporate Presentation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Jaguar Health Showcases Novel Plant-Based Gastrointestinal Medicines in Latest Corporate Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Jaguar Health Inc. <a href=\"https://laohu8.com/S/JAGX\">$(JAGX)$</a> has provided updates on its ongoing efforts to develop plant-based medicines targeting gastrointestinal disorders. The company highlighted progress with its FDA-approved product Mytesi (crofelemer 125mg delayed-release tablets), used for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar also noted the conditional FDA approval renewal of Canalevia-CA1 for the treatment of chemotherapy-induced diarrhea in dogs, with a confirmatory effectiveness trial expected to conclude in February 2026. Additionally, the presentation discussed the OnTarget study, emphasizing its significance as a first-of-its-kind trial and outlining next steps, including filing a final study report and completing a patient survey regarding diarrhea reduction. The company is also preparing for future studies in metastatic breast cancer patients and exploring expanded access for those not qualifying for enrollment. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief on December 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jaguar Health Showcases Novel Plant-Based Gastrointestinal Medicines in Latest Corporate Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJaguar Health Showcases Novel Plant-Based Gastrointestinal Medicines in Latest Corporate Presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-11 03:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Jaguar Health Showcases Novel Plant-Based Gastrointestinal Medicines in Latest Corporate Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Jaguar Health Inc. <a href=\"https://laohu8.com/S/JAGX\">$(JAGX)$</a> has provided updates on its ongoing efforts to develop plant-based medicines targeting gastrointestinal disorders. The company highlighted progress with its FDA-approved product Mytesi (crofelemer 125mg delayed-release tablets), used for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar also noted the conditional FDA approval renewal of Canalevia-CA1 for the treatment of chemotherapy-induced diarrhea in dogs, with a confirmatory effectiveness trial expected to conclude in February 2026. Additionally, the presentation discussed the OnTarget study, emphasizing its significance as a first-of-its-kind trial and outlining next steps, including filing a final study report and completing a patient survey regarding diarrhea reduction. The company is also preparing for future studies in metastatic breast cancer patients and exploring expanded access for those not qualifying for enrollment. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief on December 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JAGX","symbol_name":"Jaguar Animal Health, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL8lxWVW:1","article_id":"2590317537","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590317537","pubTimestamp":1765394455,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Jaguar Health Inc.  has provided updates on its ongoing efforts to develop plant-based medicines targeting gastrointestinal disorders. The company highlighted progress with its FDA-approved product Mytesi , used for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar also noted the conditional FDA approval renewal of Canalevia-CA1 for the treatment of chemotherapy-induced diarrhea in dogs, with a confirmatory effectiveness trial expected to conclude in February 2026. Additionally, the presentation discussed the OnTarget study, emphasizing its significance as a first-of-its-kind trial and outlining next steps, including filing a final study report and completing a patient survey regarding diarrhea reduction. The company is also preparing for future studies in metastatic breast cancer patients and exploring expanded access for those not qualifying for enrollment. You can access the full presentation through the link below.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"JAGX":"Jaguar Animal Health, Inc.","BK4007":"制药"},"translate_title":"Jaguar Health在最新的公司演示中展示了新型植物胃肠药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JAGX":0.9},"content_text":"Jaguar Health Showcases Novel Plant-Based Gastrointestinal Medicines in Latest Corporate Presentation\n    \n\n        Jaguar Health Inc. $(JAGX)$ has provided updates on its ongoing efforts to develop plant-based medicines targeting gastrointestinal disorders. The company highlighted progress with its FDA-approved product Mytesi (crofelemer 125mg delayed-release tablets), used for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar also noted the conditional FDA approval renewal of Canalevia-CA1 for the treatment of chemotherapy-induced diarrhea in dogs, with a confirmatory effectiveness trial expected to conclude in February 2026. Additionally, the presentation discussed the OnTarget study, emphasizing its significance as a first-of-its-kind trial and outlining next steps, including filing a final study report and completing a patient survey regarding diarrhea reduction. The company is also preparing for future studies in metastatic breast cancer patients and exploring expanded access for those not qualifying for enrollment. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief on December 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590317537","isCrawlerRequest":true}